Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of HMCL–CD33+ PBMC co-cultures treated with iberdomide (IBER), mezigdomide (MEZI), or pomalidomide (POM)

ABSTRACT: IBER or MEZI, POM reduced expression key inducers (macrophage migration inhibitory factor (MIF) and interleukin-10 (IL-10)) of monocytic myeloid-derived suppressor cells (M-MDSCs) in CD33+ cells and reduced proinflammatory genes such as CCL5 in HMCLs and inhibited IL-10 secretion from IL-10-producing HMCLs. This dataset explores molecular changes induced by these cytokines and the alterations in co-culture-modified gene sets in HMCLs and CD33+ cells treated with IBER or MEZI, POM.

ORGANISM(S): Homo sapiens

PROVIDER: GSE318128 | GEO | 2026/02/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profiling of the CD33+ myeloid population of PBMCs following co-culture with HDBCLs or recombinant MIF/IL-10 stimulation.

Project description:Human diffuse large B-cell lymphoma cell lines (HDBCLs) induce monocytic myeloid-derived suppressor cells (M-MDSCs) from healthy peripheral blood mononuclear cells (PBMCs) through the secretion of macrophage migration inhibitory factor (MIF) and interleukin-10 (IL-10). This dataset explores molecular changes induced by these cytokines and the time-dependent transcriptomic alterations during M-MDSC induction by co-culture with HDBCLs.

2025-08-13 | GSE303167 | GEO

Gene expression profiling of HMCL–CD33+ PBMC co-cultures treated with iberdomide (IBER), mezigdomide (MEZI), or pomalidomide (POM)

Project description:Gene expression profiling of HMCL–CD33+ PBMC co-cultures treated with iberdomide (IBER), mezigdomide (MEZI), or pomalidomide (POM)

| PRJNA1416773 | ENA

Gene expression profiling of the CD33+ myeloid population of PBMCs following co-culture with HDBCLs or recombinant MIF/IL-10 stimulation.

Project description:Gene expression profiling of the CD33+ myeloid population of PBMCs following co-culture with HDBCLs or recombinant MIF/IL-10 stimulation.

| PRJNA1294277 | ENA

RNA expression profiling of CD13/CD33-positive and CD13/CD33-negative B-ALL patients [mRNA expression]

Project description:To study the effect of expression of CD13/CD33 on the pathogenesis of B-cell acute lymphoblastic (B-ALL), we collected samples from 4 CD13/CD33-positive and 4 CD13/CD33-negative B-ALL patients and performed RNA-seq.

2023-12-31 | GSE197178 | GEO

RNA expression profiling of CD13/CD33-positive and CD13/CD33-negative B-ALL patients [miRNA expression]

2023-12-31 | GSE197180 | GEO

Klebsiella sp. CD33

Project description:Klebsiella sp. CD33 Genome sequencing

| PRJNA1280488 | ENA

Genome-wide expression profile on hiPSCs and hiPSC-derived CD33+ myeloid cells

Project description:To gain insights into which pathways might be dysregulated in JMML, we compared the transcriptome profiles among hiPSC and sorted CD33+ myeloid cells from control and patient samples. NS/JMML-derived CD33+ myeloid cells showed dysregulation in major biological processes. Moreover, a consistent expression pattern among sets of genes related to pluripotency and myeloid regulation was observed in the control, NS and NS/JMML CD33+ myeloid cells further supporting generally successful myelopoiesis. Total RNA obtained from hiPSC and sorted CD33+ myeloid cells (at day 14 of differentiation) from control and patient samples

2014-01-31 | E-GEOD-54538 | biostudies-arrayexpress

RNA-seq of CD33 KO and control HSPCs

Project description:Gene expression profile of in vitro differentiated control and CD33 KO CD34+ cells (with 70-85% CD33 KO) were analyzed by RNA-seq to exclude any major impact of CD33 loss on downstream gene expression

2018-04-26 | GSE113670 | GEO

TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease

Project description:CD33-/- and/or TREM2-/- mice were crossed with the 5xFAD mouse model of Alzheimer’s disease to generate single and double CD33/TREM2 knock-out mice on 5xFAD background. Transcriptome and gene expression analyses were performed to analyze the impact of CD33 and/or TREM2 knock-out on the transcriptome of microglia in the context of amyloid pathology. The results revealed that CD33 and/or TREM2 knock-out reprogrammed microglial gene expression signatures in 5xFAD mice in an age-dependent manner. Differential gene expression in 5xFAD;CD33-/- microglia depended on the presence of TREM2. These data suggest that TREM2 acts downstream of CD33.

2019-06-11 | GSE132508 | GEO

Gene Expression Changes in Myeloma Cells Following Short Term In-vivo Pomalidomide (Pom) or Bortezomib (Bor) Exposure

Project description:For Pom pharmacogenomic study, gene expression profiling (GEP) analyses were performed on samples from 18 patients, all of whom had received prior treatment with Len and Bor. CD138-purified plasma cells were collected from patients prior to and 48 hours after the first dose of Pom (4.0 mg/d for 2 days) and samples were hybridized to Affymetrix U133Plus2.0 arrays according to the manufacturer's recommendations. For Bor study, GEP analyses were performed on samples from 25 previously treated patients on Total Therapy 6 (TT6) trial using Affymetrix U133Plus2.0 arrays. Samples were collected prior to and 48 hours post a test dose Bor (1.0mg/m2).

2015-01-31 | E-MTAB-2441 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data